DNLI News and Press, Denali Therapeutics Inc. From 07/29/20

Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19 DNL758, discovered by Denali and partnered with Sanofi, is a small molecule inhibitor of RIPK1 that does not...

CAMBRIDGE, Mass. , July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes ther...

On Tuesday, Sanofi  (NASDAQ: SNY) and  Denali Therapeutics (NASDAQ: DNLI) announced they were halting clinical trials for one of Denali's drugs, DNL747. While the drug candidate proved to be safe at the dosage tested in the phase 1 trial, the results suggested that the molecule m...

Citing adverse findings from primate toxicity studies, Denali Therapeutics (NASDAQ: DNLI ), together with collaboration partner Sanofi (NASDAQ: SNY ), has decided to halt Phase 1b clinical trials evaluating RIPK1 inhibitor DNL747 in Alzheimer's disease and ALS and focus its resources on acce...

Denali and Sanofi pause DNL747 (a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788 (b) Denali and Sanofi intend to accelerate DNL788 for development in neurological indications, with plans to initiate clinical testing by earl...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this Read more ...

CAMBRIDGE, Mass. , May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Par...

Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brain Clinical proof of concept data with DNL310 (ETV:IDS), the first product candidate enabled by the transport vehicle technolog...

Denali Therapeutics (NASDAQ: DNLI ): Q1 GAAP EPS of -$0.55 beats by $0.02 . More news on: Denali Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ("BBB") for neurodegenerative diseases, today reported financial results ...